News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–24
Matches
24
Sources here
6
Companies here
1
Search results Stored financial headlines

Active search

24 matching headlines

Ticker or company: CNTBMain company stories
Clear
Latest

MarketBeat Analyst action

Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen has upgraded Connect Biopharma (NASDAQ:CNTB) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $7.43. The company recently reported a quarterly loss of $0.27 per share, outperforming expectations, with $2.75 million in revenue. Insider ownership stands at 22.6%, institutional ownership at 58.72%, …

Main company 🇺🇸 United States
Read at MarketBeat
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
Just inNext headlines
Stock Titan Market update Main company 🇺🇸 United States

Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A

Ikarian Capital, LLC and Neil Shahrestani have disclosed a 6.9% beneficial ownership in Connect Biopharma Holdings Limited Ordinary Shares through a Schedule 13G/A filing. This ownership amounts to 4,338,534 shares, based on 62,974,309 Ordinary Shares outstanding as of July 31, 2026. The filing indicates …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Connect Biopharma (CNTB) investor Wei Zheng discloses 4% beneficial stake

Connect Biopharma Holdings Ltd (CNTB) investor Wei Zheng has filed an amended Schedule 13G, disclosing a beneficial ownership of 2,520,359 ordinary shares, which represents a 4% stake in the company. Zheng holds sole voting and dispositive power over these shares, with the percentage based …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Investing.com Earnings Main company 🇺🇸 United States

Connect Biopharma Holdings earnings beat by ¥0.34, revenue topped estimates

Connect Biopharma Holdings (NASDAQ: CNTB) reported stronger-than-expected Q2 earnings, with an EPS of ¥-1.820, beating analyst estimates by ¥0.34. The company's revenue reached ¥18.67M, significantly surpassing the consensus estimate of ¥226.48K. Despite this, the stock has seen a 2.100% decline in the last three …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Connect Biopharma Holdings earnings beat by ¥0.33, revenue topped estimates

Connect Biopharma Holdings (NASDAQ: CNTB) reported stronger-than-expected Q2 earnings, with an EPS of ¥-1.820, beating analyst estimates by ¥0.34. The company's revenue reached ¥18.67M, significantly surpassing the consensus estimate of ¥226.48K. Despite this, the stock has seen a 2.100% decline in the last three …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
scanx.trade Earnings Main company 🇺🇸 United States

Connect Biopharma Q2 Results: Net Loss Widens To $17.3 Million

Connect Biopharma reported a Q2 2026 net loss of $17.3 million, an increase from $12.9 million in Q2 2025, primarily due to a doubling of R&D expenses to $16.3 million for Phase 2 clinical trials. Despite the widening loss, license revenue surged to $2.8 …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Connect Biopharma (NASDAQ:CNTB) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Connect Biopharma (NASDAQ:CNTB) reported quarterly earnings results, with a loss of $0.27 per share, outperforming the consensus estimate of $0.32 by $0.05. Shares rose to $2.33 in midday trading, and the company maintains a "Moderate Buy" consensus rating from analysts with an average price …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Connect Biopharma (CNTB) widens Q2 2026 loss as R&D rises, cash at $31.5M

Connect Biopharma reported a wider net loss of $17.3 million for Q2 2026, compared to $12.9 million in Q2 2025, primarily due to increased research and development expenses. Despite the loss, license and collaboration revenues surged to $2.8 million, driven by a Simcere milestone …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Connect Biopharma (CNTB) ramps rademikibart spend as losses deepen in 2026

Connect Biopharma Holdings Limited (CNTB) reported increased R&D expenses and wider net losses for the three and six months ended June 30, 2026, primarily due to expanded clinical programs for rademikibart in asthma and COPD. Despite higher collaboration revenue from a Simcere partnership, the …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts

Connect Biopharma Holdings Limited (NASDAQ:CNTB) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $7.29, significantly higher than its current price of $2.20. Director James Huang recently purchased 150,000 shares, boosting insider ownership to 22.60%. Despite missing …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Connect Biopharma Holdings Ltd (CNTB) Stock News Today

This article provides current stock information for Connect Biopharma Holdings Ltd (CNTB), including its stock price, market cap, and links to financial data, analyst ratings, and news. It indicates that more news will be available soon for the company.

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Connect Biopharma Holdings Ltd (CNTB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Connect Biopharma Holdings Ltd (CNTB) has an earnings forecast score of 8.75, ranking 63rd in its industry. Analysts have set an average price target of $7.50, with a consensus "Buy" rating based on 8 analysts. The company's expected revenue for the next quarter is …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Connect Biopharma (CNTB) Projected to Release Earnings on Wednesday

Connect Biopharma (CNTB) is anticipated to release its Q2 2026 earnings on Wednesday, August 12th, with analysts projecting a loss of $0.32 per share and revenue of $109,000. The company's previous quarter saw a loss of $0.34 per share, missing estimates. Insider ownership stands …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CNTB|Connect Biopharma Holdings Ltd|Price:2.207|Chg%:+0.157

This article provides a comprehensive stock analysis of Connect Biopharma Holdings Ltd (CNTB) by TradingKey. It highlights the company's strong fundamentals and high growth potential, despite a recent weak stock market performance. The article details CNTB's valuation as fairly valued within its industry, significant …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Connect Biopharma Holdings Ltd (CNTB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Connect Biopharma Holdings Ltd (CNTB), detailing its price momentum score of 4.73 and its current trading range between resistance at 2.60 and support at 1.79. It includes a breakdown of various technical indicators, such as MACD and …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Connect Biopharma Holdings Ltd (CNTB) Institutional Confidence

Connect Biopharma Holdings Ltd (CNTB) has an institutional shareholding score of 5.00, ranking 132nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 20.21% quarter-over-quarter to 52.97%. James Simons is the largest institutional shareholder, holding 0.21% of …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Connect Biopharma Holdings Ltd (CNTB) Cash Flow

This article provides a detailed cash flow statement for Connect Biopharma Holdings Ltd (CNTB), covering quarterly and annual data for operating, investing, and financing activities. It presents key financial figures, percentage changes, and answers frequently asked questions about different types of cash flow, their …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

ADAR1 Capital Management LLC Invests $1.95 Million in Connect Biopharma Holdings Limited Sponsored ADR $CNTB

ADAR1 Capital Management LLC recently acquired 742,400 shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) worth approximately $1.95 million, establishing a 1.18% stake in the company. Institutional investors now collectively own 58.72% of Connect Biopharma. Despite a recent quarterly loss exceeding analyst expectations, …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Connect Biopharma Holdings Ltd (CNTB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Connect Biopharma Holdings Ltd (CNTB), including its major individual and institutional investors. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activities with changes in ownership. The data highlights key investment …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Connect Biopharma Holdings Ltd (CNTB) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Connect Biopharma Holdings Ltd (CNTB), focusing on volatility, financial risk, and investment risk. It details various metrics such as Beta, VaR, maximum drawdown, daily return statistics, and Sharpe Ratio over different periods, offering a comprehensive look at …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Connect Biopharma Holdings Ltd (CNTB) Income Statement

This article provides the quarterly and annual income statements for Connect Biopharma Holdings Ltd (CNTB), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share. It also includes an FAQ section explaining how to interpret the income statement, …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Connect Biopharma Holdings Ltd (CNTB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Connect Biopharma Holdings Ltd (CNTB), stating its current valuation score is 6.10, ranking 359 out of 386 in its industry. It details the company's P/E ratio, noting its change relative to recent highs and lows, and mentions …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CNTB|Connect Biopharma Holdings Ltd|Price:2.140|Chg%:-0.060

Connect Biopharma Holdings Ltd (CNTB) is a global clinical-stage biopharmaceutical company focused on advancing rademikibart for asthma and chronic obstructive pulmonary disease. The company's stock currently trades at $2.14, with analysts giving it a "Buy" rating and a target price of $7.125. Despite recent …

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

Lake Street Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $9

Lake Street maintained a Buy rating on Connect Biopharma (CNTB.US) and kept its target price at $9.

CNTB main company
Sharemaestro market context Price above Trend Line 50 weeks +45.7% · Next-week setup negative 44.3% CNTB stored weekly price path from 5 Sep 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context